Patient enrollment is complete for a Phase 2b/3 clinical trial evaluating MN-166 (ibudilast) for ALS, developer % Medicinova ...
The ALSFRS-R is now established not only for clinical use to measure disease progression and patient status, but also as a standard outcome measure employed across ALS trials. 3,24 The Significance of ...
Conference call and webcast at 8:00 a.m. Eastern Time today NEW YORK, April 9, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc (BCLI). (NASDAQ: BCLI), a leading developer of adult stem cell ...
Please provide your email address to receive an email when new articles are posted on . The therapy was hypothesized to simultaneously mitigate mitochondrial dysfunction. The PHOENIX trial included ...
News-Medical.Net on MSN
Slow speech improves rhythm control in people with ALS
Speech rhythm, a key attribute of natural languages that directly influences the effectiveness and efficiency of ...
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/16d5db/amyotrophic_latera) has announced the addition of GlobalData 's new ...
NEW YORK, April 9, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback